Hugel's Record-High First Half Performance: Revenue and Profit Growth Details


Hugel's Record-High First Half Performance: Revenue of 25.45 Billion Won, Operating Profit of 10.37 Billion Won
Hugel achieved a record first-half revenue of 25.45 billion won and operating profit of 10.37 billion won in the first half of 2026. This marks the company's highest-ever performance, attributed to expanded overseas sales of toxin products and global market growth. Although strategic investments for establishing a direct-to-consumer model in the U.S. impacted profitability temporarily, the company recorded an 8.4% year-on-year increase in operating profit for the first half.
First Half Performance Breakdown
Hugel's first-half revenue reached 25.45 billion won, setting a new record. This represents an 8.4% year-on-year increase, driven by expanded overseas markets for toxin products and rising global brand recognition. The company notably increased its focus on direct-to-consumer sales in the U.S., which contributed to higher international revenue share.
Operating profit amounted to 10.37 billion won, up 8.4% year-on-year. However, second-quarter operating profit decreased by 1% to 56 billion won compared to the same period last year, attributed to temporary investment costs related to establishing the U.S. direct-to-consumer model. Overall, first-half performance showed improved profitability.
To better understand its overseas success, Hugel is expanding its global sales network centered on the U.S., extending to Europe and Asia. In Europe, the company collaborates with local partners through licensing agreements to boost demand, while in Asia, it focuses on acquiring new customers in Southeast Asian countries. These strategies have increased international revenue share to over 30%.
Growth Drivers and Strategy
Hugel's record performance is primarily due to expanded overseas sales of toxin products. Strategic investments for establishing a direct-to-consumer model in the U.S. initially affected profitability, but rising global brand recognition increased international revenue share, leading to improved results. This reflects Hugel's strategic approach to targeting global markets through targeted investment.
Under CEO Jang Du-hyeon, the company has maintained rapid growth despite leadership changes following the resignation of four senior executives ahead of their term expiration. The beauty business has also moved beyond its previous struggles, achieving diversified business structure.
A key part of Hugel's global strategy involves securing patent rights for toxin products while simultaneously expanding into overseas markets. In the U.S., it began filing toxin-related patents in 2025, and is pursuing similar strategies in Europe and Asia. This approach aims to establish Hugel as a global brand beyond simple product sales.
Growth Reasons and Future Outlook
Hugel's first-half growth should be examined through its overseas market expansion. Increased global demand for toxin products and the establishment of a direct-to-consumer model in the U.S. have been key drivers. Although second-quarter operating profit saw a slight 1% decline year-on-year, this is considered a temporary effect from investment costs.
Future growth will focus on solidifying Hugel's direct-to-consumer model in the U.S. and expanding overseas markets. With continued global beauty market growth expected, further revenue improvement through increased demand for toxin products is anticipated.
Establishing a direct-to-consumer model in the U.S. has temporarily increased costs but is expected to improve profitability long-term by enabling direct customer management and market share expansion. Hugel also plans to begin establishing direct-to-consumer models in Europe and Asia starting in the second half of 2026, which should contribute to further global market share growth.
Another part of Hugel's future strategy involves increasing R&D investment to strengthen competitiveness within the beauty industry. This includes developing new products and improving existing ones to maintain global competitiveness. In the first half of 2026, R&D expenses increased by 15% compared to the previous year.
Performance Data Verification and Key Notes
To verify Hugel's record first-half performance, focus on revenue of 25.45 billion won and operating profit of 10.37 billion won—both up 8.4% year-on-year from the previous year, primarily driven by expanded overseas sales of toxin products.
Second-quarter operating profit was 56 billion won, down 1% compared to the same period last year, but the first half overall showed an 8.4% increase in operating profit. This indicates that temporary investment costs related to U.S. market entry were offset by increased global sales.
Hugel's financial results were announced on August 7, 2026, with detailed data including first-half revenue and operating profit. The company also regularly publishes reports alongside financial statements detailing business strategies, allowing investors and interested readers to better understand the drivers behind performance growth.
Key Information to Note
Hugel's first-half results were confirmed through an announcement on August 7, 2026. The company reported a record revenue of 25.45 billion won and operating profit of 10.37 billion won for the first half of 2026, with particular attention to growth driven by U.S. direct-to-consumer model establishment and expanded overseas sales of toxin products.
Under CEO Jang Du-hyeon, Hugel has maintained rapid growth despite leadership changes following the resignation of four senior executives ahead of their term expiration. The beauty business has also moved beyond its previous struggles, achieving diversified business structure.
Hugel's overseas expansion strategy goes beyond simple revenue increase to establish itself as a global brand. This reflects Hugel's long-term focus on market share growth rather than short-term gains.
Frequently Asked Questions
What was the main reason for Hugel's record first-half performance?
The main reason for Hugel's record first-half performance was expanded overseas sales of toxin products and global market growth, particularly strategic investments in establishing a direct-to-consumer model in the U.S.
How did second-quarter results compare to last year?
Second-quarter operating profit decreased by 1% to 56 billion won compared to the same period last year. However, overall first-half performance showed an 8.4% increase in operating profit of 10.37 billion won compared to the previous year.
What is Hugel's future growth driver?
Hugel's future growth will focus on solidifying its direct-to-consumer model in the U.S. and expanding overseas markets, with expectations for continued revenue improvement as global beauty market growth persists.

You can view similar articles on this topic in one place.
View Related ArticlesFAQ
What was the main reason for Hugel's record first-half performance?
The main reason for Hugel's record first-half performance was expanded overseas sales of toxin products and global market growth, particularly strategic investments in establishing a direct-to-consumer model in the U.S.
How did second-quarter results compare to last year?
Second-quarter operating profit decreased by 1% to 56 billion won compared to the same period last year. However, overall first-half performance showed an 8.4% increase in operating profit of 10.37 billion won compared to the previous year.
What is Hugel's future growth driver?
Hugel's future growth will focus on solidifying its direct-to-consumer model in the U.S. and expanding overseas markets, with expectations for continued revenue improvement as global beauty market growth persists.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 휴젤 상반기 최대 실적, 매출 성장률은?